Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Genmab A/S ADR
(NQ:
GMAB
)
23.40
-0.29 (-1.22%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 3, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Genmab A/S ADR
< Previous
1
2
3
4
5
6
7
8
Next >
Genmab to Showcase Data in Various Patient Populations to be Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting
May 23, 2024
From
Genmab A/S
Via
Business Wire
Genmab Completes Acquisition of ProfoundBio
May 21, 2024
From
Genmab A/S
Via
Business Wire
7 Biotech Stocks That Could Breathe New Life Into Your Portfolio
May 20, 2024
Thanks to the underlying pertinence, these established biotech stocks to buy offer confidence to investors facing tricky market conditions.
Via
InvestorPlace
What 9 Analyst Ratings Have To Say About Genmab
May 20, 2024
Via
Benzinga
NASDAQ:GMAB is showing good growth, while it is not too expensive.
May 02, 2024
Investors seeking growth at a reasonable cost should explore GENMAB A/S -SP ADR (NASDAQ:GMAB).
Via
Chartmill
Decoding 9 Analyst Evaluations For Genmab
April 30, 2024
Via
Benzinga
NASDAQ:GMAB is not too expensive for the growth it is showing.
April 11, 2024
Via
Chartmill
Genmab to Present New and Updated Results From Multiple Clinical Trials Evaluating Epcoritamab Across Various B-Cell Malignancies at the 2024 European Hematology Association (EHA) Congress
May 14, 2024
From
Genmab A/S
Via
Business Wire
GMAB Stock Earnings: Genmab Beats EPS, Beats Revenue for Q1 2024
May 02, 2024
GMAB stock results show that Genmab beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
Via
InvestorPlace
TIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervical Cancer
April 29, 2024
From
Genmab A/S
Via
Business Wire
Is NASDAQ:GMAB on the Verge of a Major Breakout as a Strong Growth Stock?
March 28, 2024
Exploring the Growth Potential of GENMAB A/S -SP ADR (NASDAQ:GMAB) as It Nears a Breakout.
Via
Chartmill
Analyst Ratings For Genmab
March 26, 2024
Via
Benzinga
4 Analysts Assess Genmab: What You Need To Know
February 20, 2024
Via
Benzinga
Earnings Outlook For Genmab
February 13, 2024
Via
Benzinga
FDA Grants Full Approval for TIVDAK® to Treat Recurrent or Metastatic Cervical Cancer
April 29, 2024
From
Pfizer Inc.
Via
Business Wire
Why Big Pharma Is Following Novartis' Lead In A $25 Billion Market
April 25, 2024
The radiopharmaceuticals space could be worth up to $25 billion, according to one estimate.
Via
Investor's Business Daily
ProfoundBio Discovers The Joys Of Having A Wealthy Owner
April 08, 2024
Key Takeaways: Cancer treatment maker ProfoundBio announced it will be purchased by Denmark’s Genmab for $1.8 billion The deal is the fourth acquisition of a China-related innovative drugmaker by a...
Via
Benzinga
Week In Review: ProfoundBio, A Seattle-Suzhou ADC Biotech, Acquired By Genmab For $1.8 Billion
April 06, 2024
ProfoundBio will be acquired by Copenhagen’s Genmab A/S in a $1.8 billion all-cash deal. The acquisition will expand Genmab’s drug portfolio, including three ProfoundBio clinical stage ADC candidates...
Via
Talk Markets
NASDAQ:GMAB, a strong growth stock, setting up for a breakout.
February 08, 2024
Is GENMAB A/S -SP ADR (NASDAQ:GMAB) on the Verge of a Major Breakout as a Strong Growth Stock?
Via
Chartmill
Cracking The Code: Understanding Analyst Reviews For Genmab
January 29, 2024
Via
Benzinga
Genmab Slumps On Its $1.8 Billion Takeover Of Cancer Specialist ProfoundBio
April 03, 2024
Genmab is buying a privately held company focused on antibody drug conjugates.
Via
Investor's Business Daily
Genmab to Broaden and Strengthen Oncology Portfolio with Acquisition of ProfoundBio
April 03, 2024
From
Genmab A/S
Via
Business Wire
NASDAQ:GMAB is showing good growth, while it is not too expensive.
March 21, 2024
For those who appreciate growth without the sticker shock, GENMAB A/S -SP ADR (NASDAQ:GMAB) is worth considering.
Via
Chartmill
Why NASDAQ:GMAB Is a Promising High-Growth Stock in the Midst of Consolidation.
March 05, 2024
Why GENMAB A/S -SP ADR (NASDAQ:GMAB) Is a Promising High-Growth Stock in the Midst of Consolidation.
Via
Chartmill
NASDAQ:GMAB is showing good growth, while it is not too expensive.
February 29, 2024
While growth is established for GENMAB A/S -SP ADR (NASDAQ:GMAB), the stock's valuation remains reasonable.
Via
Chartmill
Investors seeking growth at a reasonable cost should explore NASDAQ:GMAB.
January 18, 2024
NASDAQ:GMAB is showing good growth, while it is not too expensive.
Via
Chartmill
U.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for Epcoritamab (EPKINLY®) for Difficult-to-Treat Relapsed or Refractory Follicular Lymphoma
February 27, 2024
From
Genmab A/S
Via
Business Wire
Investors should take note of NASDAQ:GMAB, a growth stock that remains attractively priced.
February 08, 2024
While growth is established for GENMAB A/S -SP ADR (NASDAQ:GMAB), the stock's valuation remains reasonable.
Via
Chartmill
Tisotumab Vedotin Marketing Authorization Application Validated by European Medicines Agency for Treatment of Recurrent or Metastatic Cervical Cancer
February 02, 2024
From
Genmab A/S
Via
Business Wire
What's Going On With Danish Healthcare Firm Genmab Stock?
January 23, 2024
Genmab's legal update on Darzalex: Arbitrator dismisses bid for milestone payments. Despite this, diverse revenue sources, including royalty agreements, contribute to strong growth.
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.